| P2093 | author name string | Kais Hussein | |
| | Marcus Kremer | |
| | Juergen Thiele | |
| | Stephan Dirnhofer | |
| | Hans Michael Kvasnicka | |
| | Harald Stein | |
| | Martin Werner | |
| | Hans Kreipe | |
| | Annette Schmitt-Graeff | |
| | Christine Beham-Schmid | |
| | Stephan Schwarz | |
| | Roshanak Bob | |
| P2860 | cites work | High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. | Q54357496 |
| | Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. | Q54536225 |
| | Measuring nominal scale agreement among many raters | Q56518939 |
| | Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes | Q28221962 |
| | Silver impregnation methods for reticulum fibers and reticulin: a re-investigation of their origins and specificity | Q28278867 |
| | Intraclass correlations: uses in assessing rater reliability | Q28296226 |
| | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities | Q33396730 |
| | Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents | Q33397092 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications | Q33405989 |
| | The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes | Q33407572 |
| | Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines | Q33773400 |
| | Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls | Q33843390 |
| | Bone marrow fibrosis in acute lymphoblastic leukaemia of childhood | Q33846267 |
| | Hematopathologic findings in chronic idiopathic myelofibrosis | Q36275880 |
| | Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach | Q36279234 |
| | International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). | Q36468734 |
| | Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl | Q36509782 |
| | The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera | Q36524055 |
| | Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification | Q36857937 |
| | Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading | Q36857952 |
| | Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres | Q36957972 |
| | The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. | Q38013039 |
| | Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management | Q38076672 |
| | Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens | Q44273829 |
| | Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes | Q44302357 |
| | Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients | Q44509200 |
| | World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience | Q45884600 |
| | Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms | Q45892294 |
| | Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis | Q46919614 |
| | Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. | Q50890627 |
| | Diagnosis and quantification of bone marrow fibrosis are significantly biased by the pre-staining processing of bone marrow biopsies. | Q51956105 |
| | Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. | Q53100468 |
| | Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. | Q53225234 |
| P433 | issue | 6 | |
| P304 | page(s) | 905-915 | |
| P577 | publication date | 2015-09-24 | |
| P1433 | published in | Histopathology | Q1524040 |
| P1476 | title | Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. | |
| P478 | volume | 68 | |